146 related articles for article (PubMed ID: 38084797)
1. Comparing a point-of-care urine tenofovir lateral flow assay to self-reported adherence and their associations with viral load suppression among adults on antiretroviral therapy.
Phillips T; Gomba Y; Myer L
Trop Med Int Health; 2024 Feb; 29(2):96-103. PubMed ID: 38084797
[TBL] [Abstract][Full Text] [Related]
2. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings.
Jennings L; Kellermann T; Spinelli M; Nkantsu Z; Cogill D; van Schalkwyk M; Decloedt E; van Zyl G; Orrell C; Gandhi M
AIDS Res Hum Retroviruses; 2022 Jun; 38(6):455-462. PubMed ID: 34779228
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy.
Dorward J; Lessells R; Govender K; Moodley P; Samsunder N; Sookrajh Y; Turner P; Butler CC; Hayward G; Gandhi M; Drain PK; Garrett N
J Int AIDS Soc; 2023 Sep; 26(9):e26172. PubMed ID: 37735860
[TBL] [Abstract][Full Text] [Related]
5. Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes.
Bardon AR; Dorward J; Sookrajh Y; Sayed F; Quame-Amaglo J; Pillay C; Feutz E; Ngobese H; Simoni JM; Sharma M; Cressey TR; Gandhi M; Lessells R; Moodley P; Naicker N; Naidoo K; Thomas K; Celum C; Abdool Karim S; Garrett N; Drain PK
BMJ Open; 2021 Oct; 11(10):e050116. PubMed ID: 34610939
[TBL] [Abstract][Full Text] [Related]
6. Determining the acceptability of point-of-care urine tenofovir testing and its performance in predicting HIV RNA suppression.
Marryshow TA; Muhairwe J; Tang A; Molulela MMM; Matta R; Jordan MR
Int J STD AIDS; 2022 Jul; 33(8):777-783. PubMed ID: 35611960
[TBL] [Abstract][Full Text] [Related]
7. Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study.
Odayar J; Orrell C; Phillips TK; Hu NC; Kabanda S; Malaba TR; Allerton J; Wiesner L; Hsiao NY; Castillo-Mancilla J; Lesosky M; Myer L
Clin Infect Dis; 2022 Sep; 75(5):761-767. PubMed ID: 34979553
[TBL] [Abstract][Full Text] [Related]
8. Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure.
McCluskey SM; Govender K; Adamson J; Gandhi M; Spinelli MA; Moosa MY; Muyindike W; Moodley P; Pillay M; Masette G; Sunpath H; Pillay S; Chen G; Hedt-Gauthier B; Marconi VC; Siedner MJ
AIDS; 2023 Jun; 37(7):1109-1113. PubMed ID: 36928169
[TBL] [Abstract][Full Text] [Related]
9. Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection.
Hermans LE; Umunnakwe CN; Lalla-Edward ST; Hebel SK; Tempelman HA; Nijhuis M; Venter WDF; Wensing AMJ
Clin Infect Dis; 2023 Feb; 76(3):e553-e560. PubMed ID: 36136811
[TBL] [Abstract][Full Text] [Related]
10. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
Phillips TK; Sinxadi P; Abrams EJ; Zerbe A; Orrell C; Hu NC; Brittain K; Gomba Y; Norman J; Wiesner L; Myer L; Maartens G
J Acquir Immune Defic Syndr; 2019 Jul; 81(3):311-318. PubMed ID: 30893125
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa.
Jennings L; Robbins RN; Nguyen N; Ferraris C; Leu CS; Dolezal C; Hsiao NY; Mgbako O; Joska J; Castillo-Mancilla JR; Myer L; Anderson PL; Remien RH; Orrell C;
AIDS; 2022 Jun; 36(7):933-940. PubMed ID: 35131960
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir diphosphate in dried blood spots and HIV-1 resistance in South Africa.
Singh Y; Castillo-Mancilla J; Madimabe R; Jennings L; Ferraris CM; Robbins RN; Anderson PL; Remien RH; Orrell C
AIDS Res Ther; 2023 Sep; 20(1):67. PubMed ID: 37705102
[TBL] [Abstract][Full Text] [Related]
13. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens.
van Zyl G; Jennings L; Kellermann T; Nkantsu Z; Cogill D; van Schalkwyk M; Spinelli M; Decloedt E; Orrell C; Gandhi M
AIDS; 2022 Nov; 36(14):2057-2062. PubMed ID: 36305182
[TBL] [Abstract][Full Text] [Related]
14. Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir-based antiretroviral therapy.
Dorward J; Govender K; Moodley P; Lessells R; Samsunder N; Sookrajh Y; Fanshawe TR; Turner PJ; Butler CC; Drain PK; Hayward GN; Garrett N
AIDS; 2024 Apr; 38(5):697-702. PubMed ID: 38126342
[TBL] [Abstract][Full Text] [Related]
15. Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV.
Morrow M; MaWhinney S; Coyle RP; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; Castillo-Mancilla JR
J Infect Dis; 2019 Jul; 220(4):635-642. PubMed ID: 30942881
[TBL] [Abstract][Full Text] [Related]
16. Urine point-of-care tenofovir test demonstrates strong predictive clinical and research utility.
Mustanski B; Ryan DT; Spinelli MA; Gandhi M; Newcomb ME
AIDS; 2023 Dec; 37(15):2381-2387. PubMed ID: 37696260
[TBL] [Abstract][Full Text] [Related]
17. Psychiatric Disorders, Antiretroviral Medication Adherence and Viremia in a Cohort of Perinatally HIV-Infected Adolescents and Young Adults.
Bucek A; Leu CS; Benson S; Warne P; Abrams EJ; Elkington KS; Dolezal C; Wiznia A; Mellins CA
Pediatr Infect Dis J; 2018 Jul; 37(7):673-677. PubMed ID: 29227462
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings.
Gandhi M; Wang G; King R; Rodrigues WC; Vincent M; Glidden DV; Cressey TR; Bacchetti P; Spinelli MA; Okochi H; Siriprakaisil O; Klinbuayaem V; Mugo NR; Ngure K; Drain PK; Baeten JM
AIDS; 2020 Feb; 34(2):255-260. PubMed ID: 31634188
[TBL] [Abstract][Full Text] [Related]
19. Decreases in Self-Reported ART Adherence Predict HIV Viremia Among Pregnant and Postpartum South African Women.
Phillips TK; Wilson IB; Brittain K; Zerbe A; Mellins CA; Remien RH; Orrell C; Abrams EJ; Myer L
J Acquir Immune Defic Syndr; 2019 Mar; 80(3):247-254. PubMed ID: 30422906
[TBL] [Abstract][Full Text] [Related]
20. HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.
Teasdale CA; Sogaula N; Yuengling KA; Wang C; Mutiti A; Arpadi S; Nxele M; Pepeta L; Mogashoa M; Rivadeneira ED; Abrams EJ
J Int AIDS Soc; 2018 Aug; 21(8):e25168. PubMed ID: 30094952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
